BioPharma Dive June 20, 2024
Ned Pagliarulo

Researchers reported zero infections in the study group given Gilead’s lenacapavir, and recommended the company stop the Phase 3 trial early.

Dive Brief:

  • Twice-yearly shots of a Gilead Sciences HIV drug were so effective at preventing infections in a large late-stage clinical trial that study monitors recommend the company stop testing early and offer the drug to all participants.
  • The trial, called Purpose 1 and run in South Africa and Uganda, compared Gilead’s medicine lenacapavir to once-daily Truvada and background HIV infection rates among cisgender women. Lenacapavir proved superior to both, with zero HIV infections reported in the study group, Gilead said Thursday.
  • Gilead hopes testing of twice-yearly lenacapavir will prove it an effective and more convenient preventive option...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Seattle biotech startup Bonum upgrades offices, expands team in its pursuit of cancer drugs
Public Health Matters Video: Walmart is Elevating Specialty Pharmacy Services and Enriching HIV Care
Demand for hospital pharmacists dips
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
New Gene Therapy for Muscular Dystrophy May Facilitate Development of Others

Share This Article